FLT3 and acute myeloid leukemia: With respect to the AML-categories, a more substantial blast drop under lenalidomide was noticed in AML with defining mutations, despite the fact that the presence of driver mutations such as FLT3 and NPM1 has been linked to low cytolytic activity of the tumor microenvironment [34].